On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Metastasis to buccinator lymph nodes from upper gingival cancer is rare, and indicates a poor prognosis. We suggest that the ...

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

Mohs microscopic surgery and image-guided superficial radiation therapy (IG-SRT) demonstrate high local cure rates in the management of non-melanoma skin cancer.

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

A 63-year-old woman with a 20-year history of hidradenitis suppurativa, classified as Hurley Stage III (a disease-specific staging system); a 12 pack-year smoking history; pyoderma gangrenosum; and ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesionsData support further development of BT-001 in solid tumors ...

This Melanoma Awareness Month, don’t wait. Skin cancer doesn’t slow down, and neither should you. Keep an eye on your skin but know that the most effective way to catch changes early is with regular ...

eDepartment of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands fDepartment of Medical Oncology, University Medical Center Groningen, Groningen, ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Dr Anjali Pathak discusses four cases of skin cancer or pre-cancer - involving potentially malignant skin lesions - and their management ...

A female infant presented with a month-long history of dry cough, along with two episodes of fever and increased work of ...